Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sen. Franken Tasks GAO To Explore Incentives For Rare-Disease Devices

This article was originally published in The Gray Sheet

Executive Summary

Sen. Al Franken, D-Minn., sent a 1letter to the Government Accountability Office July 21, requesting that the watchdog agency explore government incentives to spur development of medical devices to treat rare diseases

You may also be interested in...



IOM Report Advises FDA, NIH To Spur Innovation For Rare Disease Devices

FDA and NIH should consider options for stimulating high-priority device innovations to treat rare diseases, including the creation of NIH awards, R&D tax credits and "inducement" prizes, according to an Institute of Medicine report

IOM Report Advises FDA, NIH To Spur Innovation For Rare Disease Devices

FDA and NIH should consider options for stimulating high-priority device innovations to treat rare diseases, including the creation of NIH awards, R&D tax credits and "inducement" prizes, according to an Institute of Medicine report

FDA Inches Ahead On 'ASK Children' Neuro Implant Study

The ASK Children study, an unusual, FDA-led clinical trial designed to gather data about the use of neurologic devices in children, has enrolled 18 patients since launching in March 2009

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT029181

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel